If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Directorate Changes

24 Oct 2014 07:00

RNS Number : 1755V
Imperial Innovations Group plc
24 October 2014
 



24 October 2014

 

Imperial Innovations Group plc

 

Directorate Changes

 

Imperial Innovations Group plc (AIM: IVO or 'the Group', 'Innovations') announces that its non-executive director Dr Paul Atherton will not be seeking re-election at the Group's AGM on 16 December 2014 and will step down from the Board as of that date.

 

Dr Atherton was appointed to the Board on 29 April 2006, having been a director of the Group's subsidiary Imperial Innovations Ltd since September 2004. Dr Atherton currently serves on the Nomination Committee of the Board and previously served on its Remuneration and Audit Committees.

 

Separately, in accordance with its policy of voluntary compliance with the UK Corporate Governance Code, the Group has appointed non-executive director Linda Wilding to the role of Senior Independent Director with immediate effect.

 

Martin Knight, Chairman of Imperial Innovations, said:

 

"On behalf of the Board I would like to thank Paul for his ten years of service, during which he has played an important and influential role in the evolution of the Group. His experience as a successful scientific entrepreneur and the chairman of technology businesses has ensured that the perspective of founders and managers remains central to our way of doing business.

 

"In addition to his role on the board of Innovations, Paul co-founded and chaired two of our spin-out companies. Midaz Lasers was successfully sold to Coherent Inc. in 2012, and Paul continues as the chairman of Nexeon, our largest unquoted investment.

 

"We look forward to continuing to work together with Paul and thank him for the significant contribution he has made to Innovations over many years."

 

For further information contact:

 

Imperial Innovations Group plc

020 3053 8834

Martin Knight, Chairman

Jon Davies, Director of Communications

 

Instinctif Partners

020 7457 2020

Adrian Duffield/Melanie Toyne-Sewell

 

J.P. Morgan Cazenove (Nominated Adviser)

020 7742 4000

Michael Wentworth-Stanley/Alec Pratt

 

Cenkos Securities

020 7397 8900

Andy Roberts/Christopher Golden

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAEAKEDASPLFFF
Date   Source Headline
28th Jul 20157:01 amRNS£1 million seed investment in Inflowmatix
27th Jul 20157:00 amRNS£3.0 million investment in Concirrus
23rd Jul 20151:35 pmRNSDirectorate Change
14th Jul 20157:00 amRNSFurther £50m loan facility from EIB
2nd Jul 20157:00 amRNS£4.0m funding round in Impression Technologies
1st Jul 20157:00 amRNSFirst subject enrolled in Veryan Medical's study
30th Jun 20157:00 amRNSLeads £3 million investment in Abingdon Health
8th Jun 20151:18 pmRNSDirectorate Change
3rd Jun 20157:00 amRNSInnovations leads £6m funding round in Auspherix
29th May 20157:00 amRNSAppointment of Executive Chairman at Kesios
27th May 20154:05 pmRNSHolding(s) in Company
26th May 20157:01 amRNSDivests its shares of Epigeum
19th May 20157:00 amRNS£25m Series C funding round in PsiOxus
14th May 20157:00 amRNSTopiVert starts Phase I Clinical Trial
30th Apr 20153:48 pmRNSDirector's share purchase
27th Apr 20157:00 amRNSAutifony Therapeutics recruits first trial patient
15th Apr 20157:00 amRNSInnovations leads £5.9m funding round in Yoyo
27th Mar 20157:00 amRNSHalf Yearly Report
24th Mar 20154:40 pmRNSSecond Price Monitoring Extn
24th Mar 20154:35 pmRNSPrice Monitoring Extension
18th Mar 20157:00 amRNSCell Medica granted Orphan Drug designation
13th Mar 201510:07 amRNSEdison publishes research on Imperial Innovations
27th Feb 201511:48 amRNSNotice of Results
19th Feb 20157:00 amRNSCell Medica to commence cell therapy manufacture
14th Jan 201512:13 pmRNS£18 million Series B funding round in Veryan
18th Dec 20147:00 amRNSImperial named UK's top research university
16th Dec 201411:39 amRNSResult of AGM
9th Dec 20142:55 pmRNSGrant of options under SAYE Scheme
26th Nov 20143:41 pmRNSGrant of share options
25th Nov 201410:45 amRNSReplacement Director's share purchase
25th Nov 20147:00 amRNS£50 million Series B funding round in Cell Medica
24th Nov 20144:20 pmRNSDirector's share sale
12th Nov 20147:00 amRNSPosting of Annual Report and Notice of AGM
24th Oct 20147:00 amRNSDirectorate Changes
15th Oct 20147:00 amRNSFinal Results
8th Oct 20147:00 amRNSInnovations invests £1.85m in Kesios Therapeutics
5th Sep 20141:55 pmRNSNotice of Results
13th Aug 201412:43 pmRNSDirector's share sale
15th Jul 20142:08 pmRNSDirectorate Change
7th Jul 20147:14 amRNSPortfolio company Abzena announces offer price
4th Jul 20143:36 pmRNSHolding(s) in Company
23rd Jun 20143:15 pmRNSResults of Placing
23rd Jun 20147:00 amRNSPlacing to raise £150 million
19th Jun 201412:45 pmRNSResult of General Meeting
16th Jun 20147:09 amRNSPortfolio company announces intention to float
12th Jun 20147:00 amRNSImperial Innovations invests £1.5m in Cortexica
10th Jun 20147:00 amRNS£3 million funding round for Featurespace
4th Jun 20147:00 amRNSAutifony receives funding for Phase II trial
2nd Jun 20147:00 amRNSAppointment of non-executive directors
2nd Jun 20147:00 amRNSProposed Placing to raise up to £150 million

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.